This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dalbavancin Study Results To Be Presented At IDWeek 2013

CHICAGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from the company's lead product candidate, dalbavancin, will be presented in five posters during the IDWeek conference in San Francisco from October 2-6, 2013.

The following posters will be presented on Saturday, October 5, 2013:

Title: An Analysis of the Safety Profile of Dalbavancin from the Phase 2/3 Clinical Program

Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Anita Das, PhD, InClin, San Francisco, CA and Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT

Poster #: 1334

Title: Microbiologic Analyses of Target Pathogens Identified in the Dalbavancin DISCOVER Program

Authors: Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Helen Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA, Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT and George Talbot, MD, Talbot Advisors LLC, Anna Maria, FL

Poster #: 1338

Title: An Integrated Analysis of the Efficacy of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (abSSSI) from the DISCOVER Program

Authors: Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, Helen Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA, George Talbot, MD, Talbot Advisors LLC, Anna Maria, FL, Anita Das, PhD, InClin, San Francisco, CA, Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT and Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT

Poster #: 1339

Title: Concordance of Clinical Response at 48-72 hours after Initiation of Therapy and End of Treatment (EOT) in Patients with Acute Bacterial Skin and Skin Structure Infection (abSSSI) in the DISCOVER Studies

Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT, Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT, Mark Wilcox, MD, Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, George Talbot, MD, Talbot Advisors LLC, Anna Maria, FL and Helen Boucher, MD, FIDSA, Tufts New Engl Med Ctr, Boston, MA

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs